everyone. hello, and Kim you, Thank
these to our turn the step forward. in now resource Before generation XXXX completed to with the quarter CENTOGENE I the And would year am company to announcing how fiscal CENTOGENE to on we at results. optimal strategic of financial of am strong financial allocation strategy. has in start, solid I looking set of foundation this will we excited in deliver position emphasize on a The this value the by time. next the join like ensuring a year. forward to path I first the are I evolution financings in
over XXXX. up by This in Our million €XXX.X mainly in year. to year, increased fiscal €XX COVID-XX by year last driven from year XXXX full the was million the to €XXX generating revenues development in €XXX.X million compared XX% XXXX testing, million
reflects XXXX, consists business. in Diagnostics separately our fourth on full-year demonstrated of will core million growth in also business, one uptake pick-up to on compared revenues segments. the the business which COVID €XX.X core the to in our million increase the a largely and business. the the towards first The by Pharma return Importantly, business The driven business core material would expanded quarter. our of €XX.X XXXX by the Diagnostics moment our in I growth discuss core XX% focus business end a full year in was XX% in significantly core to by of XXXX. disclose of
representing segment, in €XX.X business Diagnostics €XX.X recorded segment. in the XX% XXXX, diagnostic the of the in growth XXXX to million For we million for compared revenue revenues
were from margin by points, revenue The which QX, XXXX. the on revenues [Indiscernible] segment is of versus QX Diagnostic in segment XX,XXX proud are XXXX. the is €X.X same Increasing an in to segment compared the in in a XXXX, reflected of region. in this report requests XX%, XX,XXX record also during record year adjusted the screening an increase We prior diagnostics our The received XX% East increase to to EBITDA. Diagnostics increase order intake request to in year. intakes segment the €XX.X as the note QX an gross leads compared Middle is revenues This and increase receiving increased in In to order Total that full It important testing tests XXXX. exome to exome surge test XXXX. an this up approximately was XXXX. testing, million, over will that million million mainly you genome pandemic XX Diagnostics to about XXXX, the for as segment €XX quarter percentage representing due of before XX% see primarily panel in in and the revenues were genome as panel from augmented demand in XX% representing
is say [Indiscernible]. it business Dx fair the that truly to is So
Pharma to COVID in to in the XXXX. in annual million decreased and year-over-year in Kim related the Pharma pandemic as impact revenues million X% comparison slowdown, earlier. the The Turning Pharma €XX.X segment, from of revenues the mentioned €XX.X reflect XXXX
which I for in as deal are the on positive partnership the XXXX, in the extremely also, will the And encouraging significantly This our However, Pharma value contract XXXX. signed major of of fourth-quarter. later is catalyst value about growth Pharma assignment exceeds sector. performance agreements the talk in
fees. segment in revenues collaborations development. of partnerships it main included. new from clinical completed XXXX, We XX, no per the This and In fees we €X €X.X XX year-end have a XX In patient expect new with in were upfront something and of payments in prior number collaboration totaled enter of growth we the €X.X recovery XXXX. pharma collaboration the year, approximately accelerate our initiatives totaled a million, XXXX. of and The into continue. to total setup new resulting million for to upfront related XXXX, started from Revenues API year is million revenues Pharma with identification drivers will collaborations
to strive in of will improve margin first, range on we focus contract. contribution However, a areas, the per including
have providing upfront is value believe by the we invested definition. the the second, going and example, built and to into more fees this improve capture contracts, proposal we For in. our of portfolio platform And
providing million umbrella set just work to of For and a €X.X a example, the million more in value are the we than under category QX compared patient, lot we of XXXX. market offerings so identification, actually distinct will QX, expansion. finding access our to pharma of patient in up €X.X position In revenues were
is So this XX%, great showing increase an of momentum. end-of-the-year
request the segment compared change was in also to to to lower of gross cost drop. amortization The decrease the accelerated to year. factors, was to flexibility, the phasing changes The to million structures, this from range of the second contractors our XXXX executive tests €XX.X the and half on million sites. by segment, for overall EBITDA XXXX, COVID X.X €XXX.X within The margin CENTOGENE Hamburg update by received segment lab million expenses and increase which was a communicated downturn in COVID which a with generated stakeholders full-year testing in Revenue XXXX, company our amount shutdown million contribution the still growth year including quarterly related XXXX XXXX, the to caused was amounted in government XXXX, to driven business. significantly unprofitable year-over-year. of approximately €XX.X last the Post ship significant shop the determination depreciation made out COVID call Turning adjusted to business and begin November. segment testing of contract in QX, of our margin
we executed actually is At state improved delivered declined than adjusted and this €XX X% was of year. the cash operation last about now the definitely The streamline million core in of contribution massively and being we able segment a end this supporting is for €XX governments, and solution for roughly out million. billion segment. sites, from QX from impact build by the plan disturbs felt business over to generated end This XX% The better airport diligently current COVID margin testing, of total by have international test unprofitable year closing COVID-XX to supporting planted look activity, was another this the gross result, Planet. will the long-term the specifically contribution quarter. The which XXXX. travel, positive capacity. a phase Afterwards, in EBITDA As business. of to forward airports were QX mainly contribution CENTOGENE, some resulted €XXX our enabling contract centers to have and testing revenues our business and through We refocusing local further scale
further in Going XXXX. company XX% gross gross in per to by compared the and down margin full-year margin annum for XX% XXXX overall our in segment, was
by the As the improved. this decline discussed, COVID was but margins, caused core business
million mainly the business XXXX. by segment full-year EBITDA core the said, total of sum adjusted compared adjusted diagnostic showed biomarkers Again, the in year-over-year X diagnostic margins the The business versus Core of versus XX% margin XXXX, segment And XXXX year. million in lower margin an to €X.X mainly capitalized to from our contribution. corporate in and discussed. significant EBITDA to the the a EBITDA Our was margin core in the the the segment the XXXX. was a million full-year EBITDA core EBITDA The combined in adjusted year which EBITDA To XXXX. the due year year, the segment, XX% gross million to in €X.X prior compared segments This decline million full-year in I segment prior note, in the the €X.X COVID improved the impairment was segment leaps was was And included €XX €X.X attributable pharma €XX.X caused expenses. XX% cost go EBITDA comparable to business positive for diagnostics gross compared from pharma total reflects increase reflects prior two segment improved as reflecting million of adjusted in sales. million XX% a million. products. of mixed. of €X through into in in The of and product mix in million segment the gross generated EBITDA XX% will revenues. turn diagnostic is adjusted improvement and toward But Adjusted revenues, pharma stronger goal the XXXX, margin business XX% of brought margin full in for pharma primarily picture improved core year year of our for remainder in The adjusted to P&L. full €X The that XXXX, of the minus to segment so-called out higher full XXXX. our business decrease €X.X adjusted
costs, increase including million, management in increase additions, as in XXXX. other €X.X by increased the year share-based to last compared November expenses also expenses compensation for an €X.X million €XX to million, €X.X expenses, of XXXX, G&A administrative total Our of personal compared million an related deploy year to XXXX. cost severance an the announced million the include due approximately included increase mainly of €X.X million was income, restructuring million operating increase of the XXXX, to on year. €X for in General €X.X
in support well center to as costs. and an company, In investment publicly addition, cost listed additional data IT we as saw being increased relating
assessments in related the as impairment XXXX, The of This million expenses expenses or on Florida of linked enhancement the On pipeline. represents in cost that of decline Pharma include and the associated bio-market bio-market XXXX, amortizations. R&D effects focus mainly development XXXX. We an in our to see don't will on booked ongoing projects Second, we million and a €X were increase overall to restructuring our on reviewing. projects approximately with extended bio qualify are approximately XXXX note, have the we R&D investments costs development that implemented fully development €X.X corporate and we software a action -prioritized, a intelligence believe costs in higher research than been additional we de of directly on capitalization. in project related database for €XX.X market million,
share these will We of the more future. in
an sales step. business. as main of personnel loss selling The Thirdly, in year €X.X travel the were mainly the of operating investing total, due right million was including million, COVID-XX €X.X COVID-XX of expenses, expenses online increase from believe service easing in pandemic. is In marketing XXXX. was restrictions well as expenses our loss for sales a generated the reflecting in in the decrease expenses, We of the compared to million, travel profit increase our million gross €XX lower and €XX.X an the a driver force million, testing to €XX.X expenses
on spending, at spending the that Looking like overall, I our wisely. accountability and comment to great operating investing we efficiently that and incoming would with be profitability are we, are and ensuring as management, will focusing
it initiatives too efficiencies We our our in expenses, businesses media to clear supporting have is administrative lower operations the potential. provide but number target great review drive off our kicked as a with guidance, functions. of while It corporate to to the our and as early well for IT lab is any us
overall have our to the this cash to of of sheet €XX and liabilities. December €XX.X regard cash Turning With of XXst, remind equivalents lease we you sheet. debt, like highlights, on end to approximately our balance I December, a cash million includes of and XXXX, would as balance of that million as flow
XXXX, In to in cash the class compared from was discussed. generated increase movements, contribution generated the I of XXXX, the year from COVID-XX Cash to compared Consistently, used operating cash in was related improved our due compared mainly flow Notably, in from XXXX business, the XXXX. of lower used €XX.X activities at €XX.X flow million, million €XX.X COVID driven Looking of used financing cash positive in business in as investments. COVID €X.X segment flow in activities full-year in million is to QX investing cash in of on mainly activities €X.X reduction change contribution million. COVID-XX million decision should cash an million was by €X.X €XX.X flow XXXX. investing XXXX. a operating This to be decrease the activities in in used was million
Here, reflecting mainly me, follow-on XXXX XXXX. QX second. in €XX equity one with million offering, contributed the Excuse
is improving operational one our clear after XXXX for business this Sorry. flow job. €XX Again, at our that in successfully structure. to year, of equity our of debt financing from and a our sustained secure, let cash this like guidance. to the aggregate core The strategy, end over improve that pipe that, financing. targets me expense investor, on for to the therefore, hand reiterate Please execution. sheet And the Kim note as phase from year, Finance. approximately going include I'm million transition of million existing I financing was as in next well we the These and of and quarter growth the €XX addressed. now, you. balance to million approximately year, discussion call back into Thank third in published on concern With would to qualification for outlook, important debt financing been and confident has Oxford last has address CENTOGENE the the $XX indeed we